Nanomedicine-based strategies to target and modulate the tumor microenvironment

Bárbara B. Mendes; Diana P. Sousa; João Conniot; João Conde

doi:10.1016/j.trecan.2021.05.001

Nanomedicine-based strategies to target and modulate the tumor microenvironment

Bárbara B. Mendes, Diana P. Sousa, João Conniot, João Conde

Research output: Contribution to journal › Review article › peer-review

65 Citations (Scopus)

87 Downloads (Pure)

Abstract

The interest in nanomedicine for cancer theranostics has grown significantly over the past few decades. However, these nanomedicines need to overcome several physiological barriers intrinsic to the tumor microenvironment (TME) before reaching their target. Intrinsic tumor genetic/phenotypic variations, along with intratumor heterogeneity, provide different cues to each cancer type, making each patient with cancer unique. This brings additional challenges in translating nanotechnology-based systems into clinically reliable therapies. To develop efficient therapeutic strategies, it is important to understand the dynamic interactions between TME players and the complex mechanisms involved, because they constitute invaluable targets to dismantle tumor progression. In this review, we discuss the latest nanotechnology-based strategies for cancer diagnosis and therapy as well as the potential targets for the design of future anticancer nanomedicines.

Original language	English
Pages (from-to)	847-862
Number of pages	16
Journal	Trends in Cancer
Volume	7
Issue number	9
Early online date	2 Jun 2021
DOIs	https://doi.org/10.1016/j.trecan.2021.05.001
Publication status	Published - Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

modulation
nanotechnology
targeting, therapy
tumor microenvironment

Access to Document

10.1016/j.trecan.2021.05.001

Nanomedicine-based strategies to target andmodulate the tumor microenvironmentFinal published version, 1.47 MBLicence: CC BY

Cite this

@article{e1bd4218c0c244c0adceb33348d96120,

title = "Nanomedicine-based strategies to target and modulate the tumor microenvironment",

abstract = "The interest in nanomedicine for cancer theranostics has grown significantly over the past few decades. However, these nanomedicines need to overcome several physiological barriers intrinsic to the tumor microenvironment (TME) before reaching their target. Intrinsic tumor genetic/phenotypic variations, along with intratumor heterogeneity, provide different cues to each cancer type, making each patient with cancer unique. This brings additional challenges in translating nanotechnology-based systems into clinically reliable therapies. To develop efficient therapeutic strategies, it is important to understand the dynamic interactions between TME players and the complex mechanisms involved, because they constitute invaluable targets to dismantle tumor progression. In this review, we discuss the latest nanotechnology-based strategies for cancer diagnosis and therapy as well as the potential targets for the design of future anticancer nanomedicines.",

keywords = "modulation, nanotechnology, targeting, therapy, tumor microenvironment",

author = "Mendes, \{B{\'a}rbara B.\} and Sousa, \{Diana P.\} and Jo{\~a}o Conniot and Jo{\~a}o Conde",

note = "Funding Information: The authors acknowledge financial support from Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia / Minist{\'e}rio da Ci{\^e}ncia, Tecnologia, e Ensino Superior in the framework of PhD grant 2020.06638.BD (to D.P.S.), and from the European Research Council grant agreement No 848325 (J.C. for the ERC Starting Grant). Funding Information: The authors acknowledge financial support from Funda??o para a Ci?ncia e a Tecnologia/ Minist?rio da Ci?ncia, Tecnologia, e Ensino Superior in the framework of PhD grant 2020.06638.BD (to D.P.S.), and from the European Research Council grant agreement No 848325 (J.C. for the ERC Starting Grant). None declared by authors. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = sep,

doi = "10.1016/j.trecan.2021.05.001",

language = "English",

volume = "7",

pages = "847--862",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Nanomedicine-based strategies to target and modulate the tumor microenvironment

AU - Mendes, Bárbara B.

AU - Sousa, Diana P.

AU - Conniot, João

AU - Conde, João

N1 - Funding Information: The authors acknowledge financial support from Fundação para a Ciência e a Tecnologia / Ministério da Ciência, Tecnologia, e Ensino Superior in the framework of PhD grant 2020.06638.BD (to D.P.S.), and from the European Research Council grant agreement No 848325 (J.C. for the ERC Starting Grant). Funding Information: The authors acknowledge financial support from Funda??o para a Ci?ncia e a Tecnologia/ Minist?rio da Ci?ncia, Tecnologia, e Ensino Superior in the framework of PhD grant 2020.06638.BD (to D.P.S.), and from the European Research Council grant agreement No 848325 (J.C. for the ERC Starting Grant). None declared by authors. Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021/9

Y1 - 2021/9

N2 - The interest in nanomedicine for cancer theranostics has grown significantly over the past few decades. However, these nanomedicines need to overcome several physiological barriers intrinsic to the tumor microenvironment (TME) before reaching their target. Intrinsic tumor genetic/phenotypic variations, along with intratumor heterogeneity, provide different cues to each cancer type, making each patient with cancer unique. This brings additional challenges in translating nanotechnology-based systems into clinically reliable therapies. To develop efficient therapeutic strategies, it is important to understand the dynamic interactions between TME players and the complex mechanisms involved, because they constitute invaluable targets to dismantle tumor progression. In this review, we discuss the latest nanotechnology-based strategies for cancer diagnosis and therapy as well as the potential targets for the design of future anticancer nanomedicines.

AB - The interest in nanomedicine for cancer theranostics has grown significantly over the past few decades. However, these nanomedicines need to overcome several physiological barriers intrinsic to the tumor microenvironment (TME) before reaching their target. Intrinsic tumor genetic/phenotypic variations, along with intratumor heterogeneity, provide different cues to each cancer type, making each patient with cancer unique. This brings additional challenges in translating nanotechnology-based systems into clinically reliable therapies. To develop efficient therapeutic strategies, it is important to understand the dynamic interactions between TME players and the complex mechanisms involved, because they constitute invaluable targets to dismantle tumor progression. In this review, we discuss the latest nanotechnology-based strategies for cancer diagnosis and therapy as well as the potential targets for the design of future anticancer nanomedicines.

KW - modulation

KW - nanotechnology

KW - targeting, therapy

KW - tumor microenvironment

UR - https://www.scopus.com/pages/publications/85110014003

U2 - 10.1016/j.trecan.2021.05.001

DO - 10.1016/j.trecan.2021.05.001

M3 - Review article

C2 - 34090865

AN - SCOPUS:85110014003

SN - 2405-8033

VL - 7

SP - 847

EP - 862

JO - Trends in Cancer

JF - Trends in Cancer

IS - 9

ER -

Nanomedicine-based strategies to target and modulate the tumor microenvironment

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this